Cited 0 times in

Overcoming 5-FU resistance of cancer cell by spliceosome inhibitor Pladienolide-B

Lee, Young-Joon | Chang, Da-young | Woo, Hyun-Goo | Suh-Kim, Haeyoung | Kim, Sung-Soo
Department of Biomedical Sciences, Graduate School of Ajou University  | Department of Anatomy, Ajou University School of Medicine  | Department of Physiology, Ajou University School of Medicine
One of major problem with cancer chemotherapy is cancer cell's resistance against anticancer drugs. It can be either innate or acquired during chemotherapy. The cancer drug resistance limits choice of anticancer drug and leads to bad prognosis of patients. With advanced NGS technology and RNA sequencing technique, recent studies suggest alternative splicing event as important factor in cancer drug resistance. In our study, we focus on spliceosome and it's alternative splicing modulation in drug resistance of cancer cells. Fluorouracil (5-FU) resistant cancer cell line T98FR was developed by treating T98G cell with moderate dose of 5-FU over passages. T98FR cell had highly up-regulated spliceosome related genes compared to T98G cell. In in-vitro study, T98FR cell became sensitive to 5-FU when cells were treated with Pladienolide-β, a spliceosome inhibitor. In addition, T98FR cell expressed less 5-FU metabolism genes when they were treated with Pladienolide-β
Appears in Collections:
Poster > Graduate School of Biomedical Sciences > Biomedical Sciences, The Graduate School
Poster > School of Medicine / Graduate School of Medicine > Department of Anatomy
Poster > School of Medicine / Graduate School of Medicine > Department of Physiology
Ajou Authors
대학, 생리학교실  |  대학, 해부학교실  |  대학원, 의생명과학과
Files in This Item:


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.